INTRODUCTION
Agar, composed of -D-galactose linked by -1,4 linkages and 3,6-anhydro--L-galactose linked by -1,3 linkages, can be hydrolyzed by -agarase and -agarase, respectively (1).
-agarase cleaves the -1,4 linkages of agar, producing neoagarooligosaccharides (NAO) including neoagarobiose (DP2), neoagarotetraose (DP4), and neoagarohexaose (DP6) (2) . Several reports suggest that NAO inhibit bacterial growth (3) , and stimulate macrophages (4); however, the functional analysis of DP2, DP4, or DP6, which are single compounds of NAO, has not been undertaken. In this study, we used -agarase (DagA) purified from Streptomyces coelicolor A3(2), a non-toxic, gram-positive soil bacterium that is well known for its use in the production of approximately 85% of all antibiotics (1) . However, the immunological functions of -agarase DagA-produced NAO, especially DP6, remain unclear. Therefore, we focused on the physiological functions of -agarase DagA-produced DP6, especially, its role in the activation of dendritic cell (DC)-mediated cancer immunotherapy to verify the potential of DP6 as an immunomodulatory agent.
The communication between NK cells and DCs influences both innate and adaptive immunity and enhances Th1 and CTL-mediated antitumor efficacy (5) induce the maturation of DCs and type-1 polarized DCs producing pro-inflammatory cytokines (6) . In addition, NK cell-derived IFN- up-regulates Th1 transcription factor GATA-3 (6) . The interaction between NK cells and DCs reportedly regulates NK and T-cell responses against target cells (7) .
In this study, we aimed to identify the immunological actions of the natural polysaccharide DP6. DP6 activates DCs by activating mitogen-activated protein kinases (MAPKs) and nuclear factor-B (NF-B) signaling via Toll-like receptor 4 (TLR4). In addition, the administration of DP6 showed The data are presented as the means and standard error of the mean (SEM). **P ＜ 0.01 and ***P ＜ 0.001 compared to untreated DCs. (B) ELISA was performed to measure the TNF-, IL-6, IL-1, IL-12p70, and IL-10 production in DP6-or LPS-treated DCs. The data are presented as the means and standard error of the mean (SEM, n = 3). **P ＜ 0.01 and ***P ＜ 0.001 compared to untreated DCs. (C) Endocytic activity of DP6-treated DCs. Endocytic activity of dextran-FITC uptake by DCs treated with medium, LPS, or DP6 was assessed at 37 
RESULTS

DP6 induces the activation of DCs via TLR4
To verify the products of agar hydrolysis, reaction products including DP6 were separated and identified by thin layer chromatography (TLC). As shown in Supplementary Fig. 1A , the purified single compounds, DP6 (M1), were observed on a TLC plate, as compared to DagA-derived NAO, which was used as a positive marker (M2). The purity of DP6 after gel permeation chromatography was quantified by HPLC Evaporative Light Scattering Detector (HPLC ELSD) as approximately 95% (Supplementary Fig. 1B ). To exclude the possibility of contamination with endotoxin, the purified DP6 was subjected to LAL endotoxin detection assay ( Supplementary Fig. 1C ) and silver staining ( Supplementary Fig. 2 ), followed by confirmation that the purified DP6 sample was not contaminated with endotoxins. In addition, to evaluate the cytotoxic effects of DP6 on dendritic cells (DCs), the rate of apoptosis or necrosis in DP6-treated DCs was analyzed by flow cytometry (Supplementary Fig. 1D ). While treatment with H2O2, as an apoptosis inducer, markedly increased the apoptosis, DP6 had no cytotoxic effects in DCs.
To investigate whether DP6 affects the maturation of DCs, we measured the expression of surface molecules (CD80, CD86, MHC class I, and MHC class II). The surface molecules showed increased levels of expression in DP6-treated DCs as well as LPS-treated DCs (Fig. 1A -left and right panels, respectively). In addition, the secretion of pro-and antiinflammatory cytokines (TNF-, IL-6, IL-1, IL-12p70, and IL-10) was significantly elevated in DP6-treated DCs (Fig. 1B) . Moreover, DP6 significantly diminished the percentage of dextran ＋
CD11c
＋ cells (Fig. 1C) , as compared to untreated DCs, indicating that DP6 enhances phenotypic and functional maturation of DCs.
Toll-like receptors (TLRs) are considered to play an important role in the activation of DCs (8); and TLR4 is necessary for the activation of immune cells by several natural polysaccharides (9) . Therefore, to examine whether TLR signaling is involved in DP6-mediated DC activation, the expression of surface molecules and the production of cytokines were measured in DP6-treated DCs derived from WT, TLR2 , and TLR9 −/− mice ( Fig. 2A and 2B ). Next, to investigate whether DP6 stimulates the activation of MAPKs, AKT, and NF-B, which are crucial for TLR4-mediated DC activation (10), the phosphorylation levels of MAPKs and AKT and the degradation levels of p65 in response to DP6 were identified in DCs from WT and TLR4 −/− mice ( −/− mice (six mice per group) were injected i.p. with 500 mg/ml DP6 on days −8, −6, −4, −2, 0, 2, 4, and 8 and were injected s.c. with B16F1 melanoma cells. Tumor growth was monitored by measuring the diameter of the tumor every other day. Data are expressed as the mean ± SEM. *P ＜ 0.05 compared to DP6-injected WT mice.
p38 MAPKs, JNK, and AKT in DCs from WT mice; however, it showed no effect on the phosphorylation of these kinases in DCs from TLR4 −/− mice. In addition, DP6 decreased the level of the p65 subunit of NF-B in the cytosolic fraction of DCs from WT mice but not in the cytosolic fraction of DCs from TLR4 −/− mice. These results indicated that TLR4-mediated activation of MAPKs, AKT, and NF-B might be involved in DP6-mediated DC activation.
DP6 augments TLR4-dependent antitumor immunity in vivo
Since DCs are known to induce antitumor activity by modulating immune responses (8), the possible antitumor effect of DP6 against B16F1 melanoma cells in vivo was investigated. Briefly, C57BL/6 mice were intraperitoneally (i.p.) administered PBS or DP6 (100 or 200 mg/kg), every other day and subcutaneously (s.c.) inoculated with B16F1 melanoma cells during the course of PBS or DP6 administration (Fig. 3A) . As shown in Fig. 3B , administration of 100 and 500 mg/kg DP6 showed significant inhibition of tumor growth compared to that observed in the group administered PBS (Fig. 3B) . The therapeutic effect of DP6 against B16F1 melanoma cells was shown in the treated (500 mg/kg DP6) group of mice at 18 days, as compared to the control (PBS) group at the same time-point (Fig. 3C) .
TLR4 has a role in DP6-induced DC activation (Fig. 2) ; hence, the role of TLR4 in DP6-mediated antitumor effects was investigated in WT and TLR4 −/− mice. Mice were i.p. administered 500 mg/kg DP6 every other day and s.c. inoculated with B16F1 melanoma cells during the course of DP6 http://bmbreports.org administration. Administration of DP6 significantly diminished the tumor mass in WT mice compared to that in TLR4 −/− mice administered DP6 (Fig. 3D) . DP6 showed TLR4-dependent antitumor effects on B16F1 melanoma cells in vivo.
DP6 directly and indirectly enhances the activation of NK cells in a TLR4-dependent manner and augments NK cell-mediated antitumor immunity in vitro and in vivo
It has been previously reported that NK cells are essential for killing MHC class I-negative tumor cells such as B16F1 melanoma cells (11) . DP6 showed an antitumor effect on B16F1 melanoma cells in vivo in this study (Fig. 3) (Fig. 4B) . The secretions of IFN- and TNF-were significantly elevated in culture supernatants from NK cells treated with 2.5 mg/ml of DP6 (Fig. 4C) . Taken together, these results demonstrated that DP6 contributed to NK cell activation in vitro and in vivo.
Since the results indicated that DP6 can activate both DCs (Fig. 1 ) and NK cells (Fig. 4A-C) , we determined whether DP6 controlled the crosstalk between DCs and NK cells, which is a critical factor in anti-cancer immunity (12) . To investigate whether DP6 modulates the crosstalk between DCs and NK cells, NK1. (Fig. 4D and 4E) . The data suggested that DP6 causes activation of NK cells by activating DCs via TLR4.
Next, we investigated the role of NK cells in DP6-mediated antitumor effects. The NK cell-depleted mice showed no significant difference in tumor mass and weight as compared to that observed in the group administered PBS (Fig. 4F and  4G ). These data demonstrated that NK cells are essential for DP6-mediated antitumor immunotherapy in vivo.
DISCUSSION
Several natural polysaccharides with immunostimulatory properties have been investigated to date. In addition, natural polysaccharides with immunostimulatory properties such as -glucans have been considered as a promising adjuvant to cancer immunotherapy (13) . While the immunological functions of -agarase-produced NAO have been studied (14) , those of NAO produced by nontoxic -agarase DagA from Streptomyces coelicolor A3(2) have not been studied yet. In this study, we showed that -agarase DagA-produced DP6 1) induced DC activation in a TLR4-dependant manner; 2) triggered the stimulation of NK cells in vitro and in vivo and DP6-activated DCs indirectly induced the stimulation of NK cells in vitro; and 3) induced DC-or NK cell-mediated antitumor immunity via TLR4.
The results of this study demonstrated that DP6 caused the activation of DCs via TLR4 by activating MAPKs, AKT, and NF-B (Fig. 2C) . Our study results suggested that TLR4 acts as the main receptor of DP6 in DC activation, however, other candidate receptors need to be considered because both TLR4 and dectin-1 have been reported as main receptors of -glucans, which are well-known natural polysaccharides in DCs (15) . Even though dectin-1 is a well-known receptor of polysaccharides in DCs, it is not involved in DP6-mediated DC activation (data not shown). Moreover, it is still unclear whether DP6 might be a ligand of other receptors. Therefore, further studies are required to delineate the involvement of other receptors and related intracellular signaling pathways in response to DP6 treatment.
Since DP6 induced the activation of DCs (Fig. 1) , it is possible that DP6 might be effective in cancer immunotherapy. In our experiments, we used the B16F1 melanoma cell line instead of B16F10 for cancer immunotherapy in vivo, because the B16F1 was shown to generate drug-resistant variants at a lower rate than the B16F10 (16) . As expected, DP6 administration led to a significant anti-tumor response against B16F1 melanoma cells in vivo. In general, other natural polysaccharides such as -glucan do not directly act on cancer cells but enhance antitumor immunity via activation of neutrophils, B cells, T cells, NK cells, dendritic cells, and macrophage-mediated immune responses (17) . Since NK cells are essential for the antitumor response against tumors with down-regulated expression of MHC class I molecules such as B16F1 and TC-1 P3 (A15) (18) , it is hypothesized that NK cells play a role in DP6-mediated anti-cancer activity against B16F1. The data obtained in this study demonstrated that DP6 enhances NK cell-mediated antitumor immunity, implying that DP6 administration results in antitumor effects against MHC class I down-regulated tumor cells via NK cell-mediated cytotoxicity.
The reciprocal interaction between DCs and NK cells is crucial to enhance the efficacy of anticancer immunotherapy (6) . DCs trigger NK cell functions by increasing cytotoxicity, cytokine secretion (IFN-, TNF-), and proliferation (6) 
MATERIALS AND METHODS
Animal
Female C57BL/6 mice aged 6-8 weeks were purchased from Orient (Daejeon, Korea) and female C57BL/6J TLR2 knockout mice (TLR2 
M7Btlr
/Mmjax) were purchased from the Jackson Laboratory (USA) and maintained in filter-top cages under standard conditions (12-h light/dark cycle), with food and water provided ad libitum, in a specific pathogenfree animal facility at the Korea Research Institute of Bioscience and Biotechnology. Animals were sacrificed in the CO2 chamber and organs were harvested instantly.
Cytotoxicity analysis
Bone marrow-derived dendritic cells (BMDCs) from C57BL/6 mice were treated with 0.5, 1.0, and 2.5 mg/ml DP6, 2.5 mg/ml LPS, and 10 mM H2O2 for 30 min; subsequently, a volume of CellTiter-Glo Ⓡ Reagent (Promega) was added. BMDCs were analyzed for cell viability through luminescence.
Flow cytometry analysis
The stained cells were analyzed using a FACSCalibur flow cytometer (BD Biosciences, San Jose, CA, USA), and data were processed using the Cell Quest Pro software (BD Biosciences). 
In vivo
Statistical analysis
All experiments were repeated at least three times. Turkey's multiple comparison tests were used for comparison between samples. Statistical analyses were conducted by using the GraphPad InStat software (Ver 3.1, GraphPad). The data in the graphs are expressed as the mean ± SEM.
Further information is provided in the Supplementary Methods.
